

Post COVID 19 Lung Parenchymal Disease Management Experience with Follow up Outcomes in Qatar: A Case Series

Phool Iqbal^{1,2*}, Muhammad Bilal Jamshaid^{1,3}, Aamir Shahzad^{1,4}, Zohaib Yousaf^{1,5}, Saba Nabavi Monfared⁶, Nagham D Sadik¹ and Ibrahim Fawzy Hassa²

¹Internal Medicine Department, Hamad Medical Corporation, Qatar

²Medicine Critical Care Department, Hamad Medical Corporation, Qatar

³Department of Rheumatology, Hamad Medical Corporation, Qatar

⁴Reading Hospital, Tower health, Pennsylvania, USA

⁵Dresden International University, Dresden, Germany

⁶Trauma & Emergency Clinical Pharmacist Department, Hamad Medical Corporation, Qatar.

Published November 11, 2021

ABSTRACT

Background: COVID 19 has resulted in one of the worst global pandemics in recent history. Post-COVID 19 interstitial lung disease is a significant concern in COVID-19 survivors. It is a disabling clinical condition for the patients and a burden on the healthcare system. With the passage of time and subsequent different waves of COVID 19 across the globe, post-COVID 19 sequelae of lung diseases can be debilitating.

Case Series: We report case series of three patients with persistent hypoxia post-COVID 19, raising concerns for interstitial lung disease in Qatar. We shared our experience of the patient's clinical course, complications, and outcomes in post-COVID 19 sequelae of lung parenchymal disease.

Results: The patients were followed up during and after treatment until recovery or discharge from the hospital.

Conclusion: Through our case series, we want to highlight few points. First, the approach and management strategy of post-COVID 19 lung parenchymal disease patients is individualized. Sequelae of Post COVID 19 interstitial lung diseases do not follow the same course during the follow-up period, and outcomes may differ. Two different entities are reported with regards to post-COVID 19 lung parenchymal disease. Post-COVID 19 fibrotic lung disease and fibrotic-like lesions follow different clinical courses, management strategies, and outcomes. Therefore, further studies for categorization of post-COVID 19 lung parenchymal disease and adequate follow-up at regular time intervals are required.

Keywords: Post COVID 19, Lung fibrosis, ICU, Anti-fibrotic, Pulmonary rehabilitation

Corresponding author: Phool Iqbal, Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar, E-mail: piqbal@hamad.qa

Citation: Iqbal P, Jamshaid MB, Shahzad A, Yousaf Z, Monfared SN, et al. (2021) Post COVID 19 Lung Parenchymal Disease Management Experience with Follow up Outcomes in Qatar: A Case Series. BioMed Res J, 5(S2): 05.

Copyright: ©2021 Iqbal P, Jamshaid MB, Shahzad A, Yousaf Z, Monfared SN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.